{"schema_version":"1","generated_at":"2026-11-21T18:42:18.295Z","data_as_of":null,"url":"https://www.findmykol.com/kol/aaron-eggebeen","json_url":"https://www.findmykol.com/kol/aaron-eggebeen/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"aaron-eggebeen","name":"Aaron Eggebeen","credential":"MD","specialty":"Rheumatology","specialty_raw":"Rheumatology","therapeutic_area":"Rheumatology/Immunology","therapeutic_areas":["Rheumatology/Immunology"],"institution":"Calvin University","institution_url":"https://www.findmykol.com/institution/calvin-university","city":"Grand Rapids","state":"MI","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Aaron Eggebeen is a Rheumatology/Immunology physician affiliated with Calvin University. OpenAlex indexes 6 publications with 784 citations (h-index 5).","overview":null,"focus":{"indications":[],"research_topics":["Rheumatology/Immunology"]},"scholarship":{"works_count":6,"cited_by_count":784,"h_index":5,"latest_activity_year":2021,"source":"works"},"payments":{"company_count":3,"program_years":{"first":2021,"last":null},"rows_total":3,"shown":3,"withheld":0,"rows":[{"payer":"Cardinal Health 110 LLC","program_year":2021,"amount_usd":100,"payment_count":1},{"payer":"Janssen Biotech, Inc.","program_year":2021,"amount_usd":54.52,"payment_count":4},{"payer":"Genentech USA, Inc.","program_year":2021,"amount_usd":49.95,"payment_count":1}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":9,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":59.2,"classes_total":9,"classes":[{"class":"TNF inhibitor","setting":"mixed","share_pct":39.6,"drugs":[{"name":"Infliximab","share_pct":86.5},{"name":"Enbrel Sureclick","share_pct":6.9},{"name":"Humira(Cf) Pen","share_pct":3.6},{"name":"Enbrel","share_pct":1.3},{"name":"Cimzia","share_pct":0.7},{"name":"Simponi","share_pct":0.7},{"name":"Humira(Cf)","share_pct":0.4}],"max_beneficiaries":null},{"class":"Folate Analog Metabolic Inhibitor","setting":"prescribed","share_pct":10.9,"drugs":[{"name":"Methotrexate","share_pct":96.2},{"name":"Methotrexate Sodium","share_pct":3.8}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":18.6,"classes_total":4,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":11.5,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":268},{"class":"Antidiarrheal microorganisms","setting":"prescribed","share_pct":4.1,"drugs":[{"name":"Folic Acid","share_pct":100}],"max_beneficiaries":87}]},{"area":"Nervous system","share_pct":7.9,"classes_total":6,"classes":[{"class":"Opioid Agonist","setting":"prescribed","share_pct":2.4,"drugs":[{"name":"Tramadol Hcl","share_pct":81.8},{"name":"Tramadol Hcl-Acetaminophen","share_pct":18.2}],"max_beneficiaries":null},{"class":"Gabapentinoids","setting":"prescribed","share_pct":2.3,"drugs":[{"name":"Gabapentin","share_pct":58.8},{"name":"Pregabalin","share_pct":41.2}],"max_beneficiaries":26}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":6,"shown":5,"withheld":1,"matched_by":"OpenAlex author record","recent":[{"title":"Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Therapy in Rheumatoid Arthritis","year":2017,"journal":"Medical Decision Making","source_url":"https://doi.org/10.1177/0272989x17696995","status":"verified"},{"title":"Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug","year":2013,"journal":"BMC Medical Informatics and Decision Making","source_url":"https://doi.org/10.1186/1472-6947-13-89","status":"verified"},{"title":"Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series","year":2010,"journal":"Arthritis & Rheumatism","source_url":"https://doi.org/10.1002/art.30128","status":"verified"},{"title":"Characterization and peripheral blood biomarker assessment of anti–Jo‐1 antibody–positive interstitial lung disease","year":2009,"journal":"Arthritis & Rheumatism","source_url":"https://doi.org/10.1002/art.24631","status":"verified"},{"title":"Gout: an update.","year":2007,"journal":"PubMed","status":"verified"}],"source":"works"},"similar":[{"name":"David Felson","slug":"david-felson","institution":"Boston University","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/david-felson","json_url":"https://www.findmykol.com/kol/david-felson/profile.json"},{"name":"Marc Hochberg","slug":"marc-hochberg","institution":"University of Maryland School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/marc-hochberg","json_url":"https://www.findmykol.com/kol/marc-hochberg/profile.json"},{"name":"Philip Mease","slug":"philip-mease","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/philip-mease","json_url":"https://www.findmykol.com/kol/philip-mease/profile.json"},{"name":"Michelle Petri","slug":"michelle-petri","institution":"Johns Hopkins University School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/michelle-petri","json_url":"https://www.findmykol.com/kol/michelle-petri/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":1}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}